An epidemiologist and 10-year veteran of the Fred Hutchinson Cancer Research Center, Dr. Wernli joined Group Health Research Institute (GHRI) in 2009 and began a three-year career development award in comparative effectiveness research in 2010. The award’s rich coursework, mentorship, and training opportunities support her goal of answering key questions related to cancer screening and diagnostics.
She is now leading a Patient-Centered Outcomes Research Institute (PCORI) contract to compare breast MRI (magnetic resonance imaging) to mammography for women already treated for breast cancer. There is little evidence to support the use of breast MRI for surveillance when physicians are looking for second breast cancers or recurrences of the first cancer. She is working with the Breast Cancer Surveillance Consortium (BCSC) to evaluate these two technologies. Also through the BCSC, Dr. Wernli leads a study using data on more than 800,000 women aged 40 to 79 to determine if mammographic breast density is linked to the risk of developing ovarian cancer. Additionally she is a co-investigator of GHRI’s Colorectal Cancer Screening Registry, which is part of the National Cancer Institute’s Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) program.
Dr. Wernli serves as a reviewer for several journals, including the American Journal of Epidemiology andCancer Epidemiology, Biomarkers & Prevention. A longtime member of the American Society for Preventive Oncology (ASPO), she was a recipient of the Prevent Cancer Foundation/ASPO Cancer Prevention Fellowship in 2009 and served as co-chair for the annual meeting workshop with their Young Investigators.